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Summary. The prognostic relevance of different
molecular markers in lung cancer is a crucial issue still
worth investigating, and the specimens collected and
analyzed represent a valuable source of material. Cyclin-
D1, c-erbB-2 and vascular endothelial growth factor
(VEGF) have shown to be promising as prognosticators
in human cancer. In this study, we sought to examine the
importance of Cyclin-D1, c-erbB-2 and VEGF, and to
study the quantitative relationship among these factors
and disease progression in metastases vs corresponding
primary cancer, and metastatic vs non metastatic
cancers. Material and Methods: We used
immunohistochemistry and morphometric analysis to
evaluate the amount of tumour staining for Cyclin-D1, c-
erbB-2 and VEGF in 52 patients with surgically excised
ademocarcinoma of the lung, and the outcome for our
study was survival time until death from hematogenic
metastases. Results: Metastasis presented lower c-erbB-2
expression than corresponding primary cancers (p=0.02).
Cyclin-D1 and VEGF expression were also lower in
metastases than in corresponding primary cancers, but
this difference did not achieve statistical significance.
Non-metastatic cancers also presented significantly
lower Cyclin-D1 and c-erbB-2 expression than
metastatic cancers (p<0.01 and p<0.01, respectively).
Equally significant was the difference between higher c-
erbB-2 expression by metastatic cancers compared to
non-metastatic cancers (p=0.02). Considering survival in
Kaplan-Maier analysis, Cyclin-D1 (p=0.04), c-erbB-2
(p=0.04) and VEGF (p<0.01) were important predictors
of survival in metastatic cancers. 
Conclusion: Different tumour cell profiles in metastases,
corresponding primary cancers, and non-metastatic
cancers were found, thus suggesting that different cell
clones control the invasive and non-invasive behaviour
of the cancers. The fact that cancers with higher indexes
of Cyclin-D1, cerbB-2 and VEGF expression have the
capacity to metastasize offers us the potential to guide
the use of adjuvant chemotherapy in patients likely to
fail treatment after surgical excision of cancers.
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Introduction
The incidence of lung cancer continues to rise
despite a slight decline, particularly in men, for the first
time in decades. It is now the leading cause of cancer
deaths in both sexes in Europe, United States and Brazil.
(Younes, 1997; Janssen-Heijnen et al., 1998; Wingo et
al., 1998). The overall 5-year survival for cases of non-
small cell lung cancer (NSCLC) is only 10 to 15%,
largely because the minority of cases present with
limited stage of disease that is amenable to curative
surgical resection. Despite advances in surgery,
chemotherapy, and radiotherapy in the last two decades,
the death rate has changed very little. Subjects can have
markedly different rates of disease progression in
NSCLC4, some with metastases and others with limited
disease, suggesting that these tumours, despite having
the same histological subtype, are biologically different.
Moreover, treatment success is highly dependent on
proper patient selection, illustrating the need to identify
different cell profiles in tumours that may help clinicians
to optimise therapeutic efforts for each patient,
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individually.
In this regard, many have studied molecular or other
types of markers in the primary tumour to discover what
might be related to advanced disease and shortened
survival (Baattlehner et al., 1993; Capelozzi et al., 1993;
Bernardi et al., 1995, 1997; Antonangelo et al., 1997;
Carvalho et al., 1997, 2000; Rodrigues et al., 1997;
Caporrino et al., 1999; Demarchi et al., 2000) . Because
cell cycle alteration and growth factor deregulation have
been thought to be important in tumour invasion and
metastases, a group of factors have been targeted as
potentially useful tumour markers15,16.
Among these, Cyclin-D1, c-erbB-2 and VEFG have
shown to be promising. Cyclins are key components of
cell cycle progression machinery. They activate their
partners, cyclin-dependent kinases (CDKs), which
sequentially phosphorylate critical substrates that
regulate the progression of the cell cycle. Cyclin-D1 is
expressed early in the G1phase and degrades prior to the
entrance into phase S (Jiménez-Orozco, 2001; Petty et
al., 2003; Dragnev et al., 2003). Molecular alterations of
Cyclin-D1 occur early in lung carcinogenesis and
Cyclin-D1 overexpression can be immunodetected.
When Cyclin is overexpressed, the cell decreases
transition through the cell cycle (G1-S-G2-M) and
perhaps limits the potential for repair of DNA damage
caused by carcinogen exposure.
c-erbB-2 (HER-2/neu) is a proto-oncogene located
in the long arm of chromosome 17. It codifies for a 185-
kd protein that belongs to the epidermal growth factor
receptor family and displays tyrosine kinase activity.
Although HER-2/neu has been studied most extensively
in breast cancer and its expression is limited to cancer
cells, relatively little information is available regarding
its prognostic value in lung cancer progression (Han et
al., 2002). 
Vascular endothelial growth factor (VEGF) is a 45
kDA glycoprotein, homodimeric, basic, and able to bind
heparin. It is a major regulator for angiogenesis, and
binds and activates two tyrosine kinase receptors,
VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1). These
receptors regulate physiological, as well as pathological
angiogenesis. VEGFR2 has strong tyrosine kinase
activity, and transduces the major signals for
angiogenesis21. Mutagenesis studies have shown that
only a small number of VEGF residues are important
and essential for the binding with RTK. Data described
to date from the studies of VEGF/RTK interactions agree
with the hypothesis that KDR receptor is the main
human receptor responsible for VEGF activity in both
physiological and pathological vascular development 22.
In some studies, immunostaining for Cyclin-D1, c-
erbB-2 and VEGF has also been found to be
significantly associated with the early stages of lung
cancer (Nishio et al., 1997; Keum et al., 1999; Gugger et
al., 2001), but its expression in advanced disease stages
is still to be clarified. Aiming at analysing the
importance of Cyclin-D1, c-erbB-2 and VEGF and
exploring the quantitative relationship among these
factors and progression of disease, we compared these
markers in metastases vs corresponding primary
adenocarcinomas and metastatic vs non-metastatic
adenocarcinomas and herein report our results.
Materials and methods
Patients and tumor tissues
During 1992 to 2003, from all patients with a
diagnosis of primary lung adenocarcinoma who received
surgical treatment at the Thoracic Surgery Department of
Hospital das Clinicas of the University of São Paulo
Medical School, AC Camargo Hospital of Cancer,
Hospital das Clinicas of Marilia Medical School and
Mogi das Cruzes School of Medicine (São Paulo,
Brazil), 52 patients (36 males and 16 females), mean age
63 (range, 38 to 90 years) were selected for this study.
Among these 52 patients, 27 were also submitted to
surgical resection or biopsies of hematogenic metastasis,
6 months after the primary tumor resection. Only
patients with a confirmed postoperative diagnosis were
selected for the study, based on the histopathological
diagnosis, and availability of paraffin-embedded blocks
of the primary tumours and their metastases.The
preoperative staging studies included routine history and
physical examination, biochemical survey, chest X-ray,
bronchoscopy with biopsies, CT scan of thorax and
upper abdomen, abdominal ultra sound, and bone scan;
preoperative CT scan of the brain was routinely
performed. As the main purpose of this study was to
study the profile of primary lung adenocarcinoma in
terms of invasiveness and metastatic potential, final
pathological staging was considered for the analysis. The
tumour stages were classified according to the
international union against cancer’s Tumour-Node-
Metastases classification (Montain, 2000; Gugger et al.,
2001). Among the 62 patients with primary lung
adenocarcinoma, nine patients were in stage I, 8 in stage
II, 8 in stage III and 27 in stage IV. Follow-up studies
included physical examination, chest X-ray, and blood
tests at 3-month intervals, and an additional thoracic CT
scan, abdominal ultrasound, and bronchoscopy if
necessary. Close follow-up was documented and updated
until 2006 by contacting family practitioners through
questionnaires concerning local relapse, distant
metastases, and death. 
Primary cancer tissue samples were obtained during
first surgical resection (first operation) and matching
metastases samples were obtained by diagnostic
procedures or biopsies during the course of the disease
(second operation), and fixed in 10% formalin. Their
respective paraffin-embedded blocks were sectioned at 3
µm-thickness and stained with Haematoxylin and Eosin
(H&E) (Fig. 1A,B). The histological classification of
each case was assessed by light microscopy according to
the World Health Organization guidelines (Travis et al.,
1999). 
Following the initial diagnostic evaluation, the 52
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patients with lung adenocarcinoma were divided into the
following groups: 1) metastases and corresponding
primary cancers (N=27), 2) non-metastatic cancers
(N=25). 
Immunohistochemistry
The presence of cyclin-D1, c-erbB-2 and VEGF
were analysed by immunohistochemical staining using a
LSAB kit, (Dako Co, Carpinteria, CA, K0690) in a 3
mm-thick section and mounted onto Silane-coated slides
(Sigma – cod: A3648). The antibodies used were
monoclonal mouse antihuman Cyclin-D1 (Clone DCS6,
Dako A/S, Glostrup, Denmark, M7155, at a dilution of
1:320); c-erbB-2 rabbit anti-human antibody (Dako A/S,
Glostrup, Denmark, A0485, at a dilution of 1:50); and
VEGF (clone A20, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA; dilution, 1:800). Brownish nuclear
staining was considered evidence of the Cyclin-D1
antigen expression, whereas brownish cytoplasmic
staining was evidence for the c-erbB-2 and VEGF
antigen expression by cells 
Morphometry
The immunostaining intensity and distribution were
evaluated by hot spots of the periphery of the tumor at
the peripheral edge of the proliferation, and then
quantified by conventional point-counting technique
(Gundesen et al., 1988). Briefly, in this method, a
standard microscope equipped with an eyepiece (x10)
containing a reticulated grid with 100 points and 50 lines
was used for measurements. At a magnification of x400,
the hot spots in each case were studied to quantify the
amount of points overlying stained cells. The density of
stained positive cells in hot spot areas of tumour tissue
represents the immunostaining indexes of expression and
were obtained by the following correlation:
IIE = Pp / Pt = (% section)
Where Pp / Pt represents the numbers of points
overlying stained tumour cells and total tissue or 1,000
points, respectively, expressed as a percentage.
Statistical analysis
Mean and range values for each parameter evaluated
were plotted in tables. Before proceeding to a formal
analysis of data, descriptive statistics were recorded and
graphically illustrated. To verify differences in variables
from metastases vs corresponding primary cancers and
metastatic vs non-metastatic cancers, we proceeded
toward the formal analysis of the data. In this context,
the first analysis assessed differences and associations in
the frequency of variables in metastases vs
corresponding primary cancer. For this reason, the T-test
was applied using paired sample statistics, paired sample
correlation, and paired sample tests. The second analysis
assessed differences and associations in the frequency of
variables in non-metastatic cancers versus metastatic
cancers using the T-test and ANOVA, with Tukey-HSD
or Dunnett-T3 post-hoc test for multiple comparisons,
after Shapiro-Wilk’s tests for normality and Levene’s
one-way analysis for homogeneity of variance.
Furthermore, comparisons of markers with survival were
made by Kaplan-Meier curves. All statistical procedures
were performed with SPSS version 10.0 statistical
software (SPSS, Inc., Chicago, IL). The level of
significance was set at p= 0.05.
Results
Table 1 summarizes patient’s characteristics. For
survival analyses, the median follow-up duration was 60
months (range, 1-121 months). Relapse was defined as
diagnosis of distant metastases or local recurrence.
Within the observation period, a total of 33 patients
(63%) of the 52 eligible patients died of cancer-related
causes. Throughout the course of the initial evaluation,
27 (51%) of these patients were at the M1 stage. In this
subgroup hematogenic metastases were local in 4
patients (14%), brain in 8 patients (29%), bone in 8
patients (29%), liver in 2 patients (7%), soft tissue in 4
patients (14%), and adrenal in 1 patient (1%).
Table 2 summarizes the morphometric results found
in metastases, corresponding primary cancers and non-
metastatic cancers. 
Histological variables were evaluated and compared
in 27 metastases and their corresponding primary
cancers. Cyclin-D1 was negative in 8/27 (29%)
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Table 1. Patient’s characteristics.
Total no. of patients 52
Age (yrs) 63 (38-90)a
Gender 36 males, 16 females
Overall stage
I 9
II 12
III 8
IV 33
T stage
1 24
2 15
3 7
4 1
N stage
0 25
1 19
2 5
3 3
Follow-up (months) 39 (1-133)a
Patients censored for survival analysis 33
at last time of follow-up
a: values represent median (range).
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Fig. 1. Primary lung adenocarcinoma (A) and metastatic lung adenocarcinoma (B) seen at H&E staining. x 200. Immunohistochemical staining for
Cyclin-D1 demonstrating lower expresion in cell nuclei seen in primary tumour (C) compared to metastatic tumour (D). Immunohistochemical staining
for c-erbB-2 demonstrating minimal staining of primary tumour cell cytoplasm (E) compared to metastatic lesion (F) and equally immunohistochemical
staining expression for VEGF in primary tumour (G) when compared to metastatic tumour (H). x 400
metastases and 6/27 (22%) corresponding primary
cancers. c-erbB-2 expression was negative in 3/27 (11%)
metastases and positive in all 33 corresponding primary
cancers (100%) and VEFG expression was negative in
13/27 (48%) metastases and positive in 11/27 (40%)
corresponding primary cancers. Metastasis presented
lower c-erbB-2 expression than corresponding primary
cancers (13.60±2.74, p=0.02 vs 30.92±4.47.). Cyclin-D1
and VEGF expression were lower in metastases than in
corresponding primary cancer, but this difference did not
achieve statistical significance.
Histological variables were also evaluated in 25 non-
metastatic cancers and then compared to 27 metastatic
cancers. Cyclin-D1 was negative in 11/25 non-metastatic
cancers (44%), c-erbB-2 was negative in 6/25 (24%) and
VEGF was negative in 7/25 (28%). Non-metastatic
cancers presented significantly lower cyclin D1 and c-
erbB-2 expression than metastatic cancers (8.44±2.92 vs.
44.70±6.58%, p<0.01) (Fig. 1C,D) and (13.60±2.24 vs.
48.88±4.29%, p<0.01), respectively (Fig. 1E,F). Equally
significant was the difference between higher c-erbB-2
expression by metastatic cancers compared to non-
metastatic cancers (20.6% vs 17.6%, p=0.02) (Fig.
1G,H).
Considering survival in Kaplan-Maier analysis, the
most important predictors of survival in metastatic
cancers were Cyclin D (p=0.04), c-erbB-2 (p=0.04) and
VEGF (p<0.01) expression (Fig. 2). 
Discussion
Adenocarcinomas of the lung frequently metastasize
to distant organs. Although the metastatic potential of
lung adenocarcinomas is lower than that of small cell
carcinomas, distant spread is demonstrable at diagnosis
presentation in over one-third of the cases. The usual
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Fig. 2. Kaplan-Meier survival curve for patients with non-metastatic
cancers and metastatic cancers grouped by A) Cyclin-D1 (p=0.04); B)
cerbB-2 (p=0.04) and C) VEGF (p<0.01) grouped by low and high
immuneexpression.
Table 2. Summary of morphometric resultsa.
Sub-Groups and Histological Variables Mean±SEM
Primary metastatic tumor (N=27)
Cyclin D1 (% of points) 44.70±6.58 
c-erbB-2 (% of points) 48.88±4.29
VEGF (% of points) 31.12±7.05
Hematogenic metastasis (N=27)
Cyclin D1 (% of points) 10.22±3.33
c-erbB-2 (% of points) 30.92± 4.47
VEGF (% of points) 13.70±4.76
Primary non metastatic tumor (N=25)
Cyclin D1 (% of points) 8.44±2.92
c-erbB-2 (% of points) 13.60±2.74
VEGF (% of points) 20.95±5.83
a: The units of “of points” indicate the number of points overlying the
phenomena of interest divided by the total number of points overlying
tumor. In morphometry, this is called a point fraction and is often
symbolized as Pp. Pp has been shown to approximate the volume
fraction or Vv (refer 25). 
sites of distant metastatic disease include the brain, liver,
adrenals, contralateral lung, bone and soft tissues.
Metastases may present at the same time as the primary
tumour or can occur much later, and they may be single
or multiple, clinically silent or demand emergent
diagnosis and treatment. About 60 percent of patients
with lung adenocarcinoma have evidence of
disseminated disease when they are first seen by a
physician and unfortunately are rarely cured, despite the
best efforts (Wingo et al., 1998). 
The definition of the chemotherapy role in the
treatment of this disease continues to progress and
controversy exists concerning its role and benefit in
advanced adenocarcinoma. Among the issues that have
been raised with respect to the relative value of
chemotherapy in patients with disseminated disease is
the response rate of growth tumour, usually evaluated by
serial radiological examination (Veale et al., 1993). 
Recent interest has focused on the identification of
different tumour cell features that may predict response
to treatment, growth rate, metastases and death in
patients with lung cancer. Tumour cell features may be
classified by the mechanism of action that results in
metastases, mainly growth rate and cell cycle regulation.
Tumour and metastasis growth require growth-regulating
factor, cell cycle-regulating and regulators of
vasculogenesis proteins, such as c-erbB-2, Cyclin D1
and VEGF. In addition, the aggressiveness of a tumour
depends on the features of neoplastic cells (proliferation
and expression of oncogene). There is evidence that
suggests that the interaction between Cell Cycle
Regulator, Growth Factor Receptor and Vascular
Endothelial Growth Factor influences the invasive and
metastatic profile of the tumour (Gusterson et al., 1992;
Keum et al., 1999; Shinkaruk et al., 2003; Shibuya,
2006). Differences in these aspects could, therefore,
explain differences regarding the invasive and metastatic
profiles among tumours of the same type and stage
(Demarchi et al., 2000). Furthermore, lung
adenocarcinoma displaying a wide spectrum of
clinicopathological features with varying prognosis
provide an interesting human tumour model to study the
features of the disease through the interaction between
Cell Cycle Regulator, Growth Factor Receptor and
Vascular Endothelial Growth Factor.
In this study, the effects of the interaction between
Cell Cycle Regulator (Cyclin D1), Growth Factor
Receptor (c-erbB-2) and Vascular Endothelial Growth
Factor (VEGF) in metastases vs corresponding primary
cancers and metastatic vs non-metastatic cancers were
presented. To our knowledge, the resulting effects of this
interaction have not been previously documented. We
found different tumour cell profiles in metastases,
corresponding primary cancers, metastatic and non-
metastatic cancers , thus suggesting that different cell
clones control the invasive and non-invasive behaviour
of the cancers. In fact, metastases and non-metastatic
cancers expressed low c-erbB-2, Cyclin D1 and VEGF,
while metastatic cancers expressed high c-erbB-2 with
an impact on survival of the patients.
Tumour growth and metastatic evolution depend on
growth factor regulators (Blood and Zetter, 1990;
Folkman, 1990). Data from our study demonstrated a
direct interaction between the metastases and
corresponding primary cancers. We found that Cyclin
D1, cerbB-2 and VEGF were highly expressed in
metastatic cancers, albeit low in non-metastatic cancers,
indicating that Cyclin D1, cerbB-2 and VEGF are
probably factors for growth, maintenance, progression
and metastases of the tumours. These results suggest that
actions of the Cyclin D1, c-erbB-2 and VEGF are similar
in tumour progression and are supported by the pathway
integration for metastatic progression, indicating that
tumours with higher indexes of Cyclin D1, cerbB-2 and
VEGF expression have the capacity to metastasize. The
capacity of the neoplastic cells to metastasize in
advanced tumours suggests a new tumour clone related
to angiogenesis, and is supported by some studies related
to c-erbB-2 and MMP9, a family of endopeptidase
capable of degrading basement membranes and the
extracellular matrix. MMP9 frequently are up-regulated
in malignant disease, thus facilitating tumour growth,
invasion and angiogenesis 30. Therefore, increased
tumour expression of Cyclin D1 may be more a primary
event related to cellular proliferation and differentiation,
and c-erbB-2 and VEGF secondary events related to
angiogenesis. Regardless of the mechanism, staining of
the primary tumour for Cyclin D1, cerbB-2 and VEGF
provides important prognostic information in
adenocarcinomas of the lung and their hematogenic
metastases. 
Thus, for all these reasons, we should not be
surprised to learn that Cyclin D1, cerbB-2 and VEGF
provide important prognostic information about lung
cancer, and our results now confirm the prognostic
importance of Cyclin D1, cerbB-2 and VEGF in lung
adenocarcinomas. Our results suggest that Cyclin D1,
cerbB2 and VEGF used as categorical variables, provide
more important prognostic information than does routine
pathological staging. Thus, immunohistochemical
staining for Cyclin D1, cerbB-2 and VEGF offers us the
potential to guide the use of adjuvant chemotherapy in
patients likely to fail treatment after surgical excision of
cancers or their metastases.
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